Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Haemonetics Corporation HAE
$88.48
+$2.72 (3.08%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
4247679500.00000000
-
week52high
91.39
-
week52low
50.48
-
Revenue
993196000
-
P/E TTM
43
-
Beta
0.44013800
-
EPS
1.84000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 10:00
Описание компании
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 11 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 11 авг 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 11 авг 2022 г. |
| Barrington Research | Outperform | Outperform | 11 авг 2022 г. |
| Raymond James | Outperform | Outperform | 01 июл 2022 г. |
| Mizuho | Buy | 13 окт 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 11 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 08 ноя 2022 г. |
| Mizuho | Buy | Buy | 08 ноя 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 08 ноя 2022 г. |
| Barrington Research | Outperform | Outperform | 08 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 06 янв 2023 г. |
| Citigroup | Neutral | Neutral | 12 дек 2022 г. |
| Mizuho | Buy | Buy | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Llorens Josep | D | 7173 | 2391 | 23 янв 2023 г. |
| Llorens Josep | D | 17234 | 2391 | 23 янв 2023 г. |
| Llorens Josep | A | 19625 | 2391 | 23 янв 2023 г. |
| Simon, Christopher | D | 205124 | 8600 | 11 ноя 2022 г. |
| Galvin Roy | A | 5263 | 5263 | 01 ноя 2022 г. |
| Galvin Roy | A | 2382 | 2382 | 01 ноя 2022 г. |
| Strong Stewart W | D | 15681 | 75 | 24 окт 2022 г. |
| Basil Michelle L | D | 32455 | 180 | 24 окт 2022 г. |
| Basil Michelle L | D | 12553 | 1011 | 19 сент 2022 г. |
| Basil Michelle L | D | 0 | 4213 | 19 сент 2022 г. |
Новостная лента
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
Zacks Investment Research
12 мая 2023 г. в 09:56
Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
Zacks Investment Research
11 мая 2023 г. в 09:10
Haemonetics (HAE) came out with quarterly earnings of $0.77 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.65 per share a year ago.
VREX or HAE: Which Is the Better Value Stock Right Now?
Zacks Investment Research
04 мая 2023 г. в 13:41
Investors looking for stocks in the Medical - Products sector might want to consider either VAREX IMAGING (VREX) or Haemonetics (HAE). But which of these two companies is the best option for those looking for undervalued stocks?
HAE vs. SYK: Which Stock Is the Better Value Option?
Zacks Investment Research
14 апр 2023 г. в 12:55
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Here's Why You Should Invest in Haemonetics (HAE) Right Now
Zacks Investment Research
04 апр 2023 г. в 13:42
Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.